This morning's WSJ ($) is editorializing that it may have been a big mistake, both medically and strategically, for Merck to yank the arthritis drug off the market entirely rather than strengthen warnings while leaving the drug available for patients for whom its benefits exceed its risks. Larry Ribstein was making similar arguments a few days ago, while KipEsquire also questions the "bad for everyone, should never have been marketed" view of the COX-2 inhibitor category.